Beclomethasone/Formoterol vs Fluticasone/Salmeterol in COPDBeclomethasone/Formoterol vs Fluticasone/Salmeterol in COPD
Find out which inhaler combo is quicker on the draw -- for breath in patients with COPD. BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2014 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news

GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD
In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist (also known as an anticholinergic), umeclidinium ‘UMEC’ 62.5mcg (IncruseTM Ellipta®) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol ‘FSC 250/50 mcg’ (Advair ® Diskus®), was evaluated in chronic obstructive pulmonary disease (COPD) patients over 12 weeks. (Source: GSK news)
Source: GSK news - May 19, 2014 Category: Pharmaceuticals Source Type: news

Novartis Reports Positive Ultibro Phase III Study Results For COPD
Novartis announced positive first results from the Phase III head to head LANTERN study. The study was comparing how once-daily Ultibro Breezhaler (indacaterol/glycopyrronium) improved lung function compared to twice-daily Seretide Accuhaler (salmeterol/fluticasone (SFC)) in patients with chronic obstruction pulmonary disease (COPD) with or without a history of moderate to severe exacerbations in the previous year. The trial met its primary and secondary endpoints, demonstrating Ultibro Breezhaler’s superiority over Seretide. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - May 2, 2014 Category: Pharmaceuticals Source Type: news

Glaxo Wins Injunction in Battle Over Asthma Drug
GlaxoSmithKline scored a minor victory in the battle to keep sales of its $9 billion-a-year asthma treatment Advair from being lost to generic competitors. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 24, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

GSK and Theravance reveal positive results from three Phase III trials in COPD
GlaxoSmithKline (GSK) and Theravance have reported positive results from three Phase III trials comparing Anoro Ellipta with Seretide Diskus and Advair Diskus in patients with chronic obstructive pulmonary disease (COPD). (Source: Drug Development Technology)
Source: Drug Development Technology - March 18, 2014 Category: Pharmaceuticals Source Type: news

GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies. Two studies comparin... BiopharmaceuticalsGlaxoSmithKline, Theravance, Anoro Ellipta, Advair Diskus, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2014 Category: Pharmaceuticals Source Type: news

Denmark approves generic copy of GSK's top-selling lung drug
LONDON (Reuters) - Denmark has approved the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair, threatening future sales of the British firm's biggest product. (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Denmark backs generic lung drug in threat to GSK sales
LONDON (Reuters) - Denmark has approved the sale of an inhaled lung drug that analysts think is a generic copy of GlaxoSmithKline's $8 billion-a-year blockbuster Advair, threatening its future sales. (Source: Reuters: Health)
Source: Reuters: Health - December 18, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Teva sees obstacles to copying GSK's Advair drug before 2018
LONDON (Reuters) - Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling lung drug Advair that could be sold as a true substitute to U.S. patients before 2018. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Generic Drugmaker Sees Obstacles to Copying Advair Before 2018Generic Drugmaker Sees Obstacles to Copying Advair Before 2018
Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling drug Advair (fluticasone/salmeterol) that could be sold as a true substitute to U.S. patients before 2018. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Glaxo May Face Generic Advair Sooner Than Expected
The FDA has issued a draft guidance that indicates the drugmaker may face generic competition for its best-selling Advair medication for asthma and chronic obstructive pulmonary disorder sooner than some thought. At issue is the ease with which generics may now win FDA approval based on bioequivalence and tap into a multi-billion-dollar market in just a few years. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 11, 2013 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news

FDA Offers Guidance for Advair Knockoffs
One of the world's top-selling drugs—GlaxoSmithKline's asthma treatment Advair—became more vulnerable to generic competition after the FDA issued guidance on the regulatory hurdles generics companies need to pass. (Source: WSJ.com: Health)
Source: WSJ.com: Health - September 11, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 7:43:00 PMLast Editorial Review: 7/15/2013 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - July 15, 2013 Category: Respiratory Medicine Source Type: news

fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 7:43:00 PMLast Editorial Review: 7/15/2013 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 15, 2013 Category: Drugs & Pharmacology Source Type: news

FDA Approves 'Son of Advair' for COPD ExacerbationsFDA Approves 'Son of Advair' for COPD Exacerbations
Reformulated fluticasone plus vilanterol in combination reduced exacerbations in clinical trials, but pneumonia risk remains a concern. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news